The European Haemophilia Consortium (EHC) needs funds to pursue its mission of people with rare bleeding disorders.

The EHC’s National Member Organisations (NMOs) pay an annual membership fee determined by the General Assembly.

The EHC receives external funding support from both public and private organisations. The EHC accepts financial and non-monetary support with the mutual understanding that the EHC maintains its independence and makes choices based exclusively on patients’ needs and interests. The EHC follows a strict Policy on Financial Support from Corporate Sponsors and observes strict EHC Funding Practices and Principles.

The EHC’s General Assembly meets annually and approves the organisation’s Annual and Financial Reports. The EHC’s accounts are also audited yearly and submitted to the Belgian commercial court for publication.

To read our latest Annual Report, click here. Our annual report also contains our most recent financial report.

The EHC gratefully acknowledges members of the EHC’s 2023 Corporate Giving Program (GCP):

Platinum Level: BioMarin, CSL Behring, Novo Nordisk, Roche, Sanofi, Sobi.

Gold Level:  Hemab, Pfizer, Takeda, Spark.

Silver Level: Biotest, LFB SA.